Selective Inhibition of Animal DNA Polymerases by Fat-Soluble Vitamins A,D, E and K and Their Related Compounds
Abstract:We found that fat-soluble vitamins (i.e., vitamins A, D, E and K) have novel functions such as anticancer activity, and we therefore investigated the inhibitory activity of DNA polymerases (pols) from various species by vitamins and their related compounds. In vitamin A-related compounds, fucoxanthin, astaxanthin (provitamin A), all-trans retinal (vitamin A aldehyde) and all-trans retinoic acid (vitamin A acid) inhibited the activities of mammalian replicative pols α, δ and e with IC50 values of 18-190, 14-17 and 8-30 mM, respectively, and all-trans retinol (vitamin A) did not influence any pol activities. In vitamin D-related compounds, vitamins D2 and D3 were found to be selective inhibitors of calf pol a with IC50 values of 123 and 96 μM, respectively, and provitamins D2, D3 and the active form of vitamin D3 such as 1α, 25- dihydroxyvitamin D3 could not influence any pol activities. Tocotrienols, vitamin E compounds with an unsaturated side chain with three double bonds, selectively inhibited the activity of human pol with IC50 values of 18-81 μM. In vitamin K compounds, vitamin K3 selectively inhibited mitochondrial pol γ activity with an IC50 value of 6 μM, although vitamins K1 and K2 did not inhibit the activities of any pols. On the other hand, no compounds tested influenced the activities of plant pols from cauliflower, prokaryotic pols, or DNA metabolic enzymes tested. These compounds suppressed the cell growth of a human gastric cancer cell line, NUGC-3, and halted at the G1 phase in the cell cycle. We discussed the molecular mechanism and relationship between pol inhibitory activity and anti-cancer activity by fat-soluble vitamins.
Document Type: Research Article
Affiliations: Laboratory of Food and Nutritional Sciences, Department of Nutritional Science, Kobe-Gakuin University, Nishi-ku, Kobe, Hyogo 651-2180, Japan.
Publication date: February 1, 2007
More about this publication?
- Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.